ARCHIVED - 2010 Volume 36

Advisory Committee Statements and Supplements to the CCDR

• An Advisory Committee Statement (ACS) - Statement on International Adoption ACS- 15, December 2010
• An Advisory Committee Statement (ACS) - Literature Review on Rotavirus: Disease and Vaccine Characteristics ACS- 14, November 2010
• An Advisory Committee Statement (ACS) - Statement on Risk of Injury and Travel ACS-13, November 2010
• An Advisory Committee Statement (ACS) - Update on the Use of Conjugate Pneumococcal Vaccines in Childhood ACS-12, November 2010
• An Advisory Committee Statement (ACS) - Statement for Travellers and Yellow Fever ACS-11, November 2010
• An Advisory Committee Statement (ACS) - Literature Review on One-Dose and Two-Dose Varicella Vaccination ACS-10, October 2010
• An Advisory Committee Statement (ACS) - Statement on Measles-Mumps-Rubella-Varicella Vaccine ACS-9, September 2010
• An Advisory Committee Statement (ACS) - Varicella Vaccination Two-Dose Recommendations. ACS-8, September 2010
• An Advisory Committee Statement (ACS) - Updated Recommendations For The Use Of Varicella And MMR Vaccines In HIV-infected Individuals ACS-7, September 2010
• An Advisory Committee Statement (ACS) on Seasonal Trivalent Inactivated Influenza Vaccine (TIV) for 2010-2011 ACS-6, August 2010
• An Advisory Committee Statement (ACS) Canadian Tuberculosis Committee (CTC) - Recommendations on Interferon Gamma Release Assaysfor the Diagnosis of Latent Tuberculosis Infection - 2010 Update
  ACS-5 - July 2010
• An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI) - Updated Statement on the use of Rotavirus Vaccines
  ACS-4 - July 2010
• Committee to advise on tropical medicine and Travel (CATMAT) Statement
  Statement on Pediatric Travellers
  ACS-3 - June 2010
• Committee to Advise on Tropical Medicine and Travel (CATMAT) Statement
  Statement on Pregnancy and Travel
  ACS-2 - March 2010
  CORRECTION NOTICE 2014
• An Advisory Committee Statement (ACS)
  National Advisory Committee on Immunization (NACI)
  Statement on the Recommended Use of Herpes Zoster Vaccine
  ACS-1 - January 2010

• Supplement:
  A Tool for the Potential Fall 2009 Wave of Pandemic H1N1 to Guide Public Health Decision-Making: An Overview of the Public Health Agency of Canada’s Planning Considerations, September 2009 CCDR Volume 36s3, October 2010
• Supplement:
  Advice for Consideration of Quadrivalent (A, C, Y, W135) Meningococcal Conjugate Vaccine, for use by Provinces and Territories CCDR Volume 36s2, January 2010
• Supplement:
  Guidelines for the Prevention and Control of Mumps Outbreaks in Canada CCDR Volume 36s1, January 2010